All In Biotech

Drug Trial Radar · NCT05234190

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

A Single-arm, Open-label, Multi-center, Phase I/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant.

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

33

Planned (sponsor's estimate)

Start

Jan 21, 2022

Primary completion

Feb 25, 2026

Study completion Sep 2040

Sponsor

Lead sponsor
Quell Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
Feb 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal. QEL-001 is a product made from a patients own cells, which are genetically modified and designed to help the transplant recipient's body accept their donated liver and prevent their immune system from rejecting it once immune suppression is withdrawn.

Conditions

  • Rejection; Transplant, Liver
  • Liver Failure
  • Liver Diseases

Interventions

  • QEL-001Drug

    QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 28 Days post infusion
  2. Long-term safetyTime frame: Day of infusion through to Week 82 and up to 15 years post infusion

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • H. Saint Luc

    Brussels, Belgium

  • Hopital Erasme

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • H. Clinic Barcelona

    Barcelona, Spain

  • Hospital Reina Sofia

    Córdoba, Spain

  • G. Gergorio Maranon

    Madrid, Spain

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, United Kingdom

  • King's College Hospital NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.